亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

医学 西妥昔单抗 帕妥珠单抗 曲妥珠单抗 伊立替康 结直肠癌 肿瘤科 内科学 临床终点 危险系数 无进展生存期 癌症 福尔菲里 随机对照试验 化疗 乳腺癌 置信区间
作者
Kanwal Raghav,Katherine A. Guthrie,Benjamin Tan,Crystal S. Denlinger,Marwan Fakih,Michael J. Overman,Arvind Dasari,Larry Corum,Lee G. Hicks,Mital Patel,Benjamin Esparaz,Syed Mohammad Ali Kazmi,Nitya Alluri,Sarah Colby,Sepideh Gholami,Philip J. Gold,E. Gabriela Chiorean,Scott Kopetz,Howard S. Höchster,Philip A. Philip
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
被引量:1
标识
DOI:10.1200/jco-24-01710
摘要

PURPOSE ERBB2 overexpression/amplification in RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC; human epidermal growth factor receptor 2 [HER2]-positive mCRC) appears to be associated with limited benefit from anti-EGFR antibodies and promising responses to dual-HER2 inhibition; however, comparative efficacy has not been investigated. We conducted a randomized phase II trial to evaluate efficacy and safety of dual-HER2 inhibition against standard-of-care anti-EGFR antibody–based therapy as second/third-line treatment in HER2-positive mCRC. METHODS Patients with RAS/BRAF -WT mCRC after central confirmation of HER2 positivity (immunohistochemistry 3+ or 2+ and in situ hybridization amplified [HER2/CEP17 ratio >2.0]) were assigned (1:1) to either trastuzumab plus pertuzumab (TP; trastuzumab 6 mg/kg and pertuzumab 420 mg once every 3 weeks) or cetuximab plus irinotecan (CETIRI; cetuximab 500 mg/m 2 and irinotecan 180 mg/m 2 once every 2 weeks) until progression or unacceptable toxicity. Crossover to TP was allowed after progression on CETIRI. The primary end point was progression-free survival (PFS). Secondary end points included objective response rate (ORR), overall survival, safety, and HER2 gene copy number (GCN ≥20/<20) as a predictive factor. RESULTS Between October 2017 and March 2022, 54 participants were assigned to TP (n = 26) and CETIRI (n = 28). Median PFS did not vary significantly by treatment: 4.7 (95% CI, 1.9 to 7.6) and 3.7 (95% CI, 1.6 to 6.7) months in the TP and CETIRI groups, respectively. Efficacy of TP versus CETIRI differed significantly by HER2 GCN (median PFS, GCN ≥20 [9.9 v 2.9 months] and GCN <20 [3.0 v 4.2 months], respectively; P interaction = .003). On TP, ORR was 34.6% (57.1% with GCN ≥20 v 9.1% with GCN <20) with median GCN of 29.7 versus 13.2 for responders and nonresponders, respectively ( P = .004). Grade ≥3 adverse events occurred in 23.1% and 46.1% of participants with TP and CETIRI, respectively. CONCLUSION TP appears to be a safe and effective cytotoxic chemotherapy-free option for patients with RAS/BRAF -WT, HER2-positive mCRC. Higher levels of HER2 amplification were associated with greater degree of clinical benefit from TP vis-à-vis CETIRI.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
李李发布了新的文献求助10
2秒前
整齐绿凝发布了新的文献求助10
4秒前
KYW完成签到,获得积分10
5秒前
乐乐应助Vivian采纳,获得10
11秒前
酷波er应助李李采纳,获得10
12秒前
森森完成签到,获得积分10
13秒前
整齐绿凝完成签到 ,获得积分10
21秒前
oceanL完成签到,获得积分10
34秒前
翊远完成签到,获得积分10
37秒前
充电宝应助森森采纳,获得10
46秒前
leave完成签到 ,获得积分10
55秒前
乐乐应助清新的篮球采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
王半书完成签到 ,获得积分10
1分钟前
俊逸的难破完成签到,获得积分10
1分钟前
1分钟前
花痴的沂发布了新的文献求助30
1分钟前
梅子完成签到 ,获得积分10
1分钟前
myg123完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
7_发布了新的文献求助10
1分钟前
西瓜二郎发布了新的文献求助10
1分钟前
花痴的沂完成签到,获得积分10
1分钟前
Hayat应助科研通管家采纳,获得10
1分钟前
cherlie应助科研通管家采纳,获得10
1分钟前
斯文败类应助科研通管家采纳,获得10
1分钟前
研友_VZG7GZ应助科研通管家采纳,获得10
1分钟前
cherlie应助科研通管家采纳,获得10
1分钟前
SciGPT应助科研通管家采纳,获得10
1分钟前
1分钟前
一般的完成签到 ,获得积分10
1分钟前
西瓜二郎完成签到,获得积分10
1分钟前
1分钟前
华仔应助BakerStreet采纳,获得10
2分钟前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3965570
求助须知:如何正确求助?哪些是违规求助? 3510843
关于积分的说明 11155342
捐赠科研通 3245324
什么是DOI,文献DOI怎么找? 1792823
邀请新用户注册赠送积分活动 874110
科研通“疑难数据库(出版商)”最低求助积分说明 804176